Atsena Therapeutics

About:

Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.

Website: https://atsenatx.com/

Top Investors: University of Florida, Foundation Fighting Blindness, OUP (Osage University Partners), Sofinnova Investments, Abingworth

Description:

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. Atsena has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Its pipeline of clinical and preclinical assets is powered by adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal disease, and its approach is guided by the specific needs of each patient condition.

Total Funding Amount:

$87.6M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Durham, North Carolina, United States

Founded Date:

2019-01-01

Contact Email:

info(AT)atsenatx.com

Founders:

Sanford Boye, Shannon Boye

Number of Employees:

11-50

Last Funding Date:

2023-10-02

IPO Status:

Private

Industries:

© 2025 bioDAO.ai